Skip to content

Lecanemab

Published: July 26, 2026Updated: July 26, 2026

Leqembi (lecanemab) is a monoclonal antibody medication designed to treat early-stage Alzheimer's disease by targeting and reducing amyloid beta plaques in the brain. It is specifically indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, administered as an intravenous infusion every two weeks.

Quick summary

Leqembi is an amyloid-targeting antibody infusion used to slow cognitive decline in early-stage Alzheimer's disease patients.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

RxNorm
2626149
Generic
Leqembi
Class
brand-name
Brands
—
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Leqembi is approved for the treatment of early Alzheimer's disease, specifically for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's pathology. It is not intended for patients with moderate to severe dementia.

Leqembi is a monoclonal antibody that binds to amyloid beta protofibrils (toxic soluble aggregates) and facilitates their removal from the brain, potentially slowing disease progression by reducing amyloid plaque buildup characteristic of Alzheimer's disease.

Leqembi requires regular intravenous infusions every 2 weeks and carries a boxed warning for amyloid-related imaging abnormalities (ARIA), which may include brain swelling or microbleeds. Patients require MRI monitoring during treatment. Common side effects include infusion-related reactions, headache, and ARIA. Treatment should be initiated and supervised by physicians experienced in Alzheimer's diagnosis and management.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy